Hints and tips:
Related Special Reports
...“My view is you should give them the benefit of the doubt because quite honestly, on everything that they’ve had thrown at them, they’ve checked the box,” she said....
...In its London lawsuit filed with the High Court, Moderna said BioNTech and Pfizer had obtained “significant benefits” from the sale of “infringing products”....
...Panuwat’s company, Medivation, was bought in 2016 by Pfizer for $14bn. But the stock he purchased at the time was not that of Medivation....
...At one point pharmaceutical company Pfizer even set out a “no jerks” policy....
...The Connecticut-based company stands to benefit from the growing market for migraine medicines as a new generation of drugs proves more effective....
...“Merck and Pfizer did not conduct new clinical trials to check that their drugs were still effective,” he said, with original trials only showing “marginal benefits”....
...Pfizer will keep the commercialisation rights outside the US and Japan. Roivant owns 75 per cent of Telavant, while Pfizer owns 25 per cent....
...The FTC argued that Amgen could use the rebates it pays on its “blockbuster” drugs to press insurance companies and pharmacy benefit managers into paying for two of Horizon’s medicines: Tepezza for an autoimmune...
...Shares in Pfizer added about 1 per cent on Friday, while Seagen was up about 0.9 per cent....
...That’s probably not good for long-term relationships and that type of thing and to benefit public health,” he said....
...Shares in oncology-focused biotech Seagen, which Pfizer has agreed to buy for $43bn, also fell amid fears the agency could target other deals in the sector....
...A person familiar with the EMA approval process said at the time that the drug had been “a bit of a disappointment” and that 30 per cent efficacy “started to be on the limits of [what is considered] benefit...
...The oncology-focused biotech agreed a $43bn deal to be acquired by Pfizer....
...Illumina’s market capitalisation is roughly $33bn, about a quarter of Amgen’s and well below Pfizer’s $246bn valuation....
...These investments drive innovations that benefit patients, such as new dosing regimens, delivery methods and combinations with other drugs that provide real benefits to patients, they say....
...The game is available to play for free, but players can use its in-game currency, V-Bucks, to buy virtual items, from outfits to accessories and weapons, to personalise their characters....
...Iain Simpson, analyst at Barclays, said Haleon would benefit from independent control of its balance sheet....
...However, panel members were unanimous that the benefits of both vaccines to infants outweighed any risks....
...“Parents need to know that the process for authorisation of the vaccine for their kids was thorough and that it demonstrated that the benefits of vaccination outweigh the potential risks,” she said....
...But in the final vote, just one member of 22 on the advisory panel abstained, while the remaining 21 members agreed the benefits of authorising the vaccine outweighed any potential risks....
...A version of this article was first published by Nikkei Asia on February 14 2023. ©2023 Nikkei Inc. All rights reserved....
...ExxonMobil’s stock market recovery first began when Pfizer et al announced that they had developed a strong slate of anti-Covid vaccines in November 2020....
...“The decision to allow the fourth vaccine to vulnerable populations is probably correct and it may give a little benefit — but not enough to support the decision to give it to all of the population,” she...
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
...The benefits of the Covid-19 vaccines outweigh the potential risks of rare side effects, such as the heart condition myocarditis, they argue....
International Edition